NCT02706249View on ClinicalTrials.gov

Study Of Weight-Based Versus Standard Dose Enoxaparin Thromboprophylaxis In High-Risk Hospitalized Cancer Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

December 7, 2020

Study Completion Date

June 7, 2021

Conditions
Venous Thormboembolism
Interventions
DRUG

Enoxaparin

Trial Locations (2)

44195

Cleveland Clinic Foundation, Cleveland

02215

Beth Israel Deaconess Medical Center, Boston

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Dana-Farber Cancer Institute

OTHER

NCT02706249 - Study Of Weight-Based Versus Standard Dose Enoxaparin Thromboprophylaxis In High-Risk Hospitalized Cancer Patients | Biotech Hunter | Biotech Hunter